Three Most-Debated Stocks in Pharma

研报英文原文证据摘录

Three Most-Debated Stocks in Pharma

d

Futures Act 2001 (Singapore). If there are any matters arising from, or in connection with this material, please contact JSL, located at 80 Raffles Place

#15-20, UOB Plaza 2, Singapore 048624, telephone: +65 6551 3950. In Dubai, this material is issued and distributed by Jefferies International Limited, Dubai

branch, and is intended solely for Professional Clients and should not be distributed to, or relied upon by, Retail Clients (as defined by DFSA). A distribution of

ratings in percentage terms in each sector covered is available upon request from your sales representative. In Japan, this material is issued and distributed

by Jefferies Japan Company Limited to institutional investors only. In Hong Kong, this report is issued and approved by Jefferies Hong Kong Limited

and is intended for use only by professional investors as defined in the Hong Kong Securities and Futures Ordinance and its subsidiary legislation. In the

Republic of China (Taiwan), this report should not be distributed. The research in relation to this report is conducted outside the People’s Republic of China

(“PRC”). This report does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant

qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the

relevant governmental authorities themselves. In India, this report is made available by Jefferies India Private Limited. In Australia, this report is issued

and/or approved for distribution by, or on behalf of, Jefferies (Australia) Securities Pty Ltd (ACN 610 977 074), which holds an Australian financial services

license (AFSL 487263).